“The paper highlights the need for continued public support for R&D for Covid-19 vaccines. It is structured as a conversation between Professor Giuseppe Remuzzi, scientific director of the “Mario Negri” Institute for Pharmacological Research, and Professor Massimo Florio, economist principal investigator of the study “Mapping of long-term public and private investment in the development of COVID-19 vaccines”, for the European Parliament. Questions dealt with include a) virus mutations and vaccine adaptation, b) Efficacy and duration, c) Clinical effectiveness, d) Safety, and e) target population. The paper is concuded by some social cost-benefit analysis remarks about the creation in the EU of a public infrastructure for R&D and delivery of drugs and vaccines in the public interest”

Click here to read the working paper.